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Detection of CMV DNA in bone marrow
transplant recipients: plasma versus leucocyte
polymerase chain reaction
P C Y Woo, S K F Lo, K Y Yuen, J S M Peiris, H Siau, E K W Chiu, R H S Liang,
T K Chan
Abstract
Aims-To compare the nested polymerase
chain reaction (PCR) assay for the detec-
tion of cytomegalovirus (CMV) DNA in
peripheral blood leucocytes and plasma
obtained from heparinised blood; to de-
termine the efficiency of various DNA
extraction methods to minimise inhibition
ofplasma PCR and their effect on the sen-
sitivity of plasma PCR; to determine the
inhibitory effect of heparin, dextran, and
EDTA on the CMV PCR assay.
Methods-217 heparinised blood speci-
mens from 58 bone marrow transplant
patients were processed and the sensitivi-
ties and specificities of the PCR assays
using peripheral blood leucocytes and
plasma (with simple, Instagene, and
Geneclean extraction methods) were com-
pared to those of conventional CMV
culture. In a separate experiment, dilu-
tions ofheparin, dextran, and EDTA were
included in PCR assays.
Results-The detection of CMV DNA
using peripheral blood leucocytes for PCR
assay was significantly more sensitive
(100%) than when using plasma (60%).
Instagene and Geneclean extraction re-
moved inherent inhibition but did not
improve the sensitivity ofthe plasma PCR
reaction. Heparin had an inhibitory effect
on PCR.
Conclusions-PCR assay using peripheral
blood leucocytes is better than plasma for
guiding the prescription of ganciclovir to
bone marrow transplant patients. Heparin
is inhibitory to the plasma PCR reaction.
( Clin Pathol 1997;50:231-235)
Keywords: cytomegalovirus; bone marrow transplant;
polymerase chain reaction.
Bone marrow transplantation is one of the well
recognised methods of treatment for malignant
and non-malignant haematological diseases,
some solid tumours, and metabolic disorders.
Opportunistic infections that occur as a result
of severe immunosuppression have always been
a major cause of morbidity and mortality in
bone marrow transplant patients. The nature of
the infection is dependent on the period oftime
after bone marrow transplant.' During the
post-engraftment period (day 30 to day 100),
human cytomegalovirus (CMV) is one of the
most common pathogens in these patients, in
whom the most serious manifestation is CMV
pneumonitis. Although ganciclovir is recom-
mended as the drug of choice for CMV disease,
the decision on to whom it should be given and
when has always been difficult because of its
myelosuppressive properties. Giving ganciclo-
vir prophylaxis to bone marrow transplant
patients who were seropositive for CMV and to
seronegative recipients who received bone
marrow or blood products from seropositive
donors has caused unnecessary bone marrow
suppression.2 On the other hand, giving ganci-
clovir treatment only to those whose leucocyte
or broncho-alveolar lavage (BAL) fluid tested
positive for CMV by shell vial or conventional
cell cultures (requiring at least two or 14 days,
respectively) is too late as the disease has
progressed to a more advanced stage.3 Hence
newer diagnostic methods are required to
minimise the overuse of ganciclovir prophylaxis
and avoid withholding ganciclovir from those
who would benefit from it. The development of
rapid diagnostic methods to detect CMV DNA
or antigen in plasma or buffy coat5 have facili-
tated earlier and more specific detection of
CMV disease, and allowed the earlier institu-
tion of antiviral therapy.
In this longitudinal study two rapid meth-
ods, the nested polymerase chain reaction
(PCR) assay for the detection ofCMV DNA in
plasma and peripheral blood leucocytes ob-
tained from heparinised blood, were evaluated.
Heparinised blood is frequently used for the
detection of CMV DNA in plasma.6 7 How-
ever, heparin has been reported to be an
inhibitor of PCR.8-' We therefore investigated
whether plasma obtained from heparinised
blood is a suitable clinical specimen for the
detection of CMV DNA by PCR. In addition
the effects of another anticoagulant, ethylene
diaminetetra-acetic acid (EDTA), and dextran,
used in processing blood specimens, on the
sensitivity of the PCR assay were studied.
Three DNA extraction methods were also
evaluated for their efficiency in removing PCR
inhibitors from plasma.
Methods
This study included 217 specimens from 58
patients who underwent bone marrow trans-
plantation in Queen Mary Hospital in Hong
Kong (1991-93).
SPECIMEN COLLECTION AND PROCESSING
Ten millilitres ofheparinised blood (containing
500 U heparin) were taken weekly from each
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patient from engraftment (absolute neutrophil
count in peripheral blood > 0.5xIO91l) to day
100 after bone marrow transplantation or until
the patient died. Plasma and buffy coat were
extracted as follows. The blood was mixed with
an equal volume of 6% (wt/vol) dextran
suspended in phosphate buffered saline (PBS)
and was left at 37°C for 30 minutes for
sedimentation. The upper cloudy layer was
centrifuged at 1500 rpm for 10 minutes and
the supernatant fluid (that is the plasma) was
stored at -20°C before further processing. The
pellet was suspended in hypotonic saline at 4°C
for three minutes to lyse residual red blood
cells, followed by rinsing in PBS. This last step
was repeated and the sedimented peripheral
blood leucocytes were harvested.
The plasma and peripheral blood leucocytes
were further processed for the nested PCR
assay. The plasma was filtered through a 0.45
gm filter and 100 gl of the filtrate was digested
with 100 gl of lysing buffer (containing protein-
ase K at 120 jtg/ml) at 56°C for one hour. The
protease was inactivated at 95°C for 10
minutes. An aliquot, specified below, was used
for plasma PCR. Peripheral blood leucocytes
were resuspended in distilled water at a
concentration of 2x106 cells/ml and boiled for
15 minutes; 50 gl of the boiled suspension was
used for the leucocyte PCR.
CONVENTIONAL CMV CULTURE
Peripheral blood leucocytes were suspended in
Eagle's minimal essential medium (EMEM),
and inoculated onto a monolayer of human
embryonic lung fibroblasts maintained in
EMEM supplemented with 2% fetal calf
serum, at a final concentration of 2x 106
leucocytes/ml. The culture was incubated in
5% CO, at 37°C for up to six weeks. Inspection
for cytopathic effects was carried out twice a
week. All positive results were further con-
firmed by the detection of an immediate early
antigen ofCMV in cells using indirect immuno-
fluorescence (Chemicon, USA). A confirmed
positive CMV culture, representing positive
viraemia in patients, was used as an indicator of
CMV disease.
EXTRACTION OF CMV DNA
DNA ofCMV in plasma was extracted by three
different methods. In the simple extraction, 10
,ul of supernatant fluid was used for plasma
PCR after inactivation of protease and cen-
trifugation. The remaining sample was split
and processed separately using two commercial
kits, following instructions from the manufac-
turer. In the Instagene extraction method, 50 ,ul
of the supernatant fluid was mixed with 200 ,ul
Instagene Purification matrix (Bio-Rad, Cali-
fornia, USA) and incubated at 56°C for 30
minutes. The mixture was vortexed, heated to
100°C in a screw capped Eppendorf tube on a
heat block for eight minutes, vortexed again,
and centrifuged at 12 000 rpm for three
minutes; 50 gl of the supernatant fluid was
used for plasma PCR. In the Geneclean
extraction method, 50 gl of the supernatant
fluid was mixed with three volumes of 6 M
sodium iodide solution and 5 gl of Glassmilk
suspension (Biol 01, California, USA). After
pelleting and washing with 70% (vol/vol) etha-
nol, DNA was eluted in 250 gl distilled water;
50 gl of the DNA preparation was used for
plasma PCR.
POLYMERASE CHAIN REACTION
The two-tube nested PCR assay was modified
from a published protocol." All DNA extracts
and controls were denatured at 95°C for 15
minutes and chilled in ice for five minutes. For
initial amplification with 0.5 jM external
primers (CMTR1 5'-CTGTCGGTATGGT
CTCTTC-3', CMTR2 5'-CCCGACACGCG
GAAAAGAAA-3') (Applied Biosystems model
380A synthesiser, Applied Biosystems, Califor-
nia, USA), the PCR mixture (100 gl) contained
denatured peripheral blood leucocytes or
plasma DNA, PCR buffer (10 mM Tris-HCl
pH 8.3,50 mM KCl, 3mM MgCl2, and 0.0 1%
gelatin), 200 ,uM of each deoxynucleoside
triphosphates (dNTPs), and 2.5 U Taq
polymerase (Perkin-Elmer Cetus, Norwalk,
USA). Each sample was amplified in 30 cycles
of 94°C for one minute, 55°C for one minute,
and 72°C for one minute, and with a final
extension at 72°C for 10 minutes in an
automated thermal cycler (Perkin-Elmer
Cetus, Gouda, The Netherlands). For subse-
quent amplification with 0.5 jM internal
primers (CMTR3 5'-TCTCTGGTCCTGA
TCGTCTT-3', CMTR4 5'-GTGACCTACC
AACGTAGGTT-3') (Applied Biosystems
model 380A synthesiser), 10 ,ul of the first PCR
product was transferred to a new PCR reaction
mixture of the same composition and final vol-
ume as before. The PCR conditions for
denaturation, annealing, and extension, as well
as the number of cycles, were as outlined
above. Cloned amplicon, a construct with the
segment of the morphological transforming
region II (mtr II) gene of CMV amplified by
CMTR1 and CMTR2 cloned into pUC19
(Boehringer Mannheim, Germany), and dis-
tilled water were used as the positive and nega-
tive controls, respectively. Procedures for
avoiding false positive results were followed
strictly.'2 To minimise false negative results due
to the presence of inhibitors in the samples, a f
globin control was included in parallel with
every sample in the leucocyte PCR assay,'3 and
a control spiked with 100 copies ofCMV DNA
accompanied each clinical sample in the
plasma PCR assay.
DETECTION AND CONFIRMATION OF AMPLIFIED
PRODUCTS
Ten microlitres of each final PCR product were
electrophoresed in 2% (wt/vol) agarose gel
(Promega, Madison, USA), with a molecular
size marker ('DX-1 74 DNA Hae III digest;
Promega, Madison, USA) in parallel. Electro-
phoresis in Tris-borate-EDTA (TBE) buffer
was performed at 120 V for one hour. The gel
was stained with ethidium bromide (0. 5 jg/ml)
for 15 minutes, rinsed, and photographed
under ultraviolet light illumination. A 168 bp
fragment- located within the morphological
transforming region II (mtr II) of the CMV
genome was generated in positive samples.'4
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(0.15, 0.03, and 0.015% (wt/vol)), and EDTA
(0.045 mg/ml) were used to determine the
possible inhibitory effect of these substances on
the CMV PCR reactions; 1.25 U/ml heparin,
0.15% dextran, and 0.045 mg/ml EDTA
corresponded to the final concentrations of
these substances in routine plasma PCR
experiments using heparinised or EDTA blood
samples.
STATISTICS
The results were compared using the x2 test
(Sigmastat for Windows 1.0). A p value of <
0.05 was considered statistically significant.
P|~ 168 bp
,,
1 2 3 4 5 6 7 8
Figure 1 Detection ofCMVDNA. DNA products from the nested peripheral blood
leucocyte PCR were electrophoresed on a 2% agarose gel (top) and probed by Southern
hybridisation (bottom) with an oligonucleotide probe containing a DNA sequence internal
to primer sequence used in the nested PCR. Lanes 1 and 3, positive controls with 100 copies
of CMVgenome; lane 5, negative control containing distilled water; lanes 2, 4, 6, and 7,
blood samples taken from separate patients; lane 8, molecular marker: foXI 74 Hae III
digest. Results of the gel electrophoresis agree with those obtained by the Southern blot. The
arrows indicate the PCR product of 168 bp.
Table Comparison of the sensitivity and specificity ofPBL and plasma PCR assays
with reference to conventional CMV culture
Conventional CMV culture
Number (lo) with Number (oo) with
PCR assay positive viraemia negative viraemia
Type Result (n= 15) (n=202)
PBLPCR Positive 15 (100)* 59 (29)t
Negative 0 (0) 143 (71)
Plasma PCR
Simple extraction Positive 9 (60)* 21 (10)t
Negative 6 (40) 181 (90)
Instagene extraction Positive 10 (67) 24 (12)
Negative 5 (33) 178 (88)
Geneclean extraction Positive 4 (27) 8 (4)
Negative 11 (73) 194 (96)
*p<0.01 by x' test.
tp<0.001 by x2 test.
Southern blotting,'5 hybridisation using the
radioactive oligonucleotide 5'-TGACGCGG
AGATCTTGCAATCTGGTCGCGT-3' (Ap-
plied Biosystems Model 380A synthesiser) and
autoradiography was performed for the confir-
mation of correctly amplified segment in the
first 100 samples.
EFFECT OF HEPARIN, DEXTRAN, AND EDTA ON
THE PCR ASSAY
Fresh PCR mixtures containing 100 copies of
CMV DNA spiked with various dilutions of
heparin (1.25, 0.25, and 0.125 U/ml), dextran
Results
Conventional CMV culture was used as the
gold standard to detect the presence or absence
of viraemia in patients. Fifteen samples ob-
tained from eight patients were positive by
conventional CMV culture (with an onset of
CMV viraemia ranging from day 24 to day 94
(median day 59) after transplantation), of
which all were positive for CMV DNA as
detected by the peripheral blood leucocyte
PCR assay (fig 1), achieving a sensitivity of
100% (table 1). Among these 15 specimens,
only nine were positive for CMV DNA as
detected by the plasma PCR assay using simple
extraction, representing a sensitivity of 60%. In
the remaining 202 blood samples with negative
CMV culture result, 59 (29%) and 21 (10%)
were positive for CMVDNA as detected by the
leucocyte PCR and plasma PCR assays,
respectively, with corresponding specificities of
71 and 90% (table 1). Statistical significant
differences in sensitivity (p < 0.01) and specifi-
city (p < 0.001) between results obtained by
leucocyte and plasma PCR were observed.
The clinical relevance of these results by
PCR was correlated with episodes of CMV
disease. In the eight disease episodes (repre-
sented by the 15 positive CMV cultures)
among bone marrow transplant patients,
plasma PCR assay would miss one completely
and show delayed detection of two one week
after CMV cultures became positive. In
contrast, leucocyte PCR assay did not miss any
disease episode. However, false positives were
detected. The peripheral blood leucocyte and
plasma PCR assays were positive in 15 and four
patients, respectively, in whom cultures for
CMV had never been positive.
The possibility of reduced or zero amplifica-
tion due to the presence of inhibitors in
heparinised blood samples was investigated.
For plasma PCR, inhibitor was present in 81
negative samples (40%), as there was no
amplification among the corresponding 81
samples spiked with CMV DNA. Extraction by
Instagene and Geneclean reduced inhibition in
negative specimens to 15% and 5%, respec-
tively, as the corresponding controls spiked
with CMV DNA were amplified successfully,
but neither method improved the sensitivity of
plasma PCR (table 1). On the other hand, there
was successful amplification of the 3 globin
gene in all the corresponding controls of the
negative samples for leucocyte PCR, showing
that inhibitor was absent in these samples.
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Figure 2 Dextran, heparin and EDTA as possible inhibitors of nested PCR assay for CMVDNA. Lanes 1-3, dextran at
0.15%, 0.03%, 0.015%, respectively; lanes 4-6, heparin at 1.25 U/ml, 0.25 Ulml, 0.125 Ulml, respectively;lanes 7-9,
negative control with distilled water; lane 10, EDTA (0.045 mglml);lane 11, positive control with 100 copies ofCMV
DNA; lane M, DNA molecular marker XI 74 Hae III digest.
The effect of heparin, dextran, and EDTA
on the amplification of control CMV DNA by
nested PCR is shown in fig 2. Dextran and
EDTA did not interfere with the assay.
However, heparin was profoundly inhibitory
even when diluted to 10-fold its usual concen-
tration in the reaction mix for plasma PCR
(0.0 125 U/ml).
Discussion
The development of a rapid, minimally inva-
sive, and highly sensitive method in a routine
laboratory for screening bone marrow trans-
plant patients for the presence ofCMV disease
is crucial in deciding to whom ganciclovir
should be given. In our bone marrow trans-
plant patients, detection of CMV DNA using
peripheral blood leucocytes obtained from
heparinised blood for PCR achieved a sensitiv-
ity of 100%, which makes the assay a suitable
method for screening CMV disease in bone
marrow transplant patients. If the leucocyte
CMV PCR assay is negative for a particular
patient, one may conclude with confidence that
the patient is unlikely to have an active CMV
disease. All patients tested positive by this
method must be further assessed by other
assays for CMV disease (for example, pp65
antigenaemia assay7 or shell vial culture for
detection of early antigen expression' 4), as well
as looking for clinical signs and symptoms of
CMV disease.
Both plasma and leucocytes obtained from
peripheral blood anticoagulated with either
heparin or EDTA have been used for the
detection of CMV DNA by PCR assay in
patients with or without bone marrow trans-
plants, but conflicting results have been
reported and no conclusion on the most
appropriate source of CMV DNA has been
reached.6 7 1623 In one study with bone marrow
transplant patients in which plasma obtained
from heparinised blood was used, a sensitivity
of 100% was reported compared to conven-
tional CMV culture, though the assay was not
performed in parallel with a peripheral blood
leucocyte PCR assay.6 On the other hand, two
studies on bone marrow transplant patients
showed that CMV DNA was often detected in
leucocytes before the onset of CMV disease,
and CMV DNA in plasma samples was usually
detected after the onset of CMV disease.22 23
Nevertheless, neither of these reports men-
tioned the type of anticoagulant used in their
blood samples, nor the possibility of any
inhibitor problem. In our study, when
heparinised blood was used the sensitivity of
the peripheral blood leucocyte PCR assay
(100%) was significantly higher than that ofthe
plasma PCR assay (60%).
Heparin, which had a profoundly inhibitory
effect on the PCR reactions even at 0.0125
U/ml (fig 2), is likely to contribute to the rela-
tively low sensitivity and the inhibitor problem
in the negative samples of plasma PCR assays.
It has been reported that heparin is an
exogenous inhibitor to PCR assays in at least
three studies.8-" In one study, heparinase was
reported to be effective in eliminating the
inhibitory effect of heparin, but heparinase
treatment must be followed by treatment with
Ca"+ (1.3 mM) and glycol-etherdiamine-tetra-
acetic acid (EGTA, 13.5 mM), but an EGTA
concentration of above 5 mM would inhibit
PCR."° Therefore heparinase treatment of the
heparinised blood samples would not be feasi-
ble in our CMV PCR assay. On the other hand,
heparin did not seem to interfere with the
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peripheral blood leucocyte PCR assay, as all
heparin in the blood was removed after rinsing
in PBS and suspending the pellet in distilled
water.
Besides heparin, plasma itself inhibits PCR
(unpublished observation). It has been re-
ported that endogenous PCR inhibitors are
present in different clinical samples such as
urine, stool, sputum, vitreous fluid, aqueous
fluid, and other body tissues, and various
methods including dilution, phenolchloroform
extraction, column extraction immunomag-
netic separation, guanidium thiocyanate ex-
traction, capture resin, and dialysis gel purifica-
tion could be used to reduce the inhibitory
effects." 2-29 In our study, although most of the
inhibitor problem was removed after Instagene
or Geneclean extraction, a failure in improving
the sensitivities of the PCR assays might be
related to the loss of significant proportion of
CMV DNA during extraction.
Apart from the inhibitor problem in plasma
PCR, another reason for the relatively higher
sensitivity of the peripheral blood leucocyte
PCR is the larger amount of template in leuco-
cytes than in plasma. The plasma was diluted
in turn by dextran and lysing buffer, with or
without purification matrix, before PCR,
whereas a fixed number of leucocytes (2x106
cells/ml) was used for the leucocyte PCR. Fur-
thermore, the concentration of CMV DNA in
leucocytes was higher than in plasma, as CMV
replicates actively in peripheral blood leuco-
cytes.
In order to achieve the best possible results,
an adequate concentration of leucocytes has to
be added to the PCR mixture. Manual count-
ing of cells by haemocytometer is labour inten-
sive and time consuming when the number of
samples for processing is high. An alternative
would be to use automated methods, such as
the Coulter counter or flow cytometry for cell
counting,'0 which would increase the feasibility
of PCR assay using leucocytes as a routine
diagnostic assay.
In conclusion, detection of CMV DNA by
nested PCR using peripheral blood leucocytes
is more sensitive than using plasma from
heparinised blood in bone marrow transplant
recipients. Therefore leucocyte PCR, which
can be completed within 10 hours, is a more
useful screening test in helping to decide on the
group of bone marrow transplant recipients to
whom ganciclovir should be given.
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